Annual General Meeting of Kuros Biosciences approves all resolutions - Seite 2
Sandya von der Weid
Investors
+41 78 680 0538
svonderweid@lifesciadvisors.com
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland
and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced biologic that has already been used across three
continents in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit kurosbio.com.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the
negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any
forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The
Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
End of Media Release
Language: | English |
Company: | Kuros Biosciences AG |
Wagistrasse 25 | |
8952 Schlieren | |
Switzerland | |
Phone: | +41 44 733 4747 |
Fax: | +41 44 733 4740 |
E-mail: | info@kurosbio.com |
Internet: | www.kurosbio.com |
ISIN: | CH0325814116 |
Valor: | 32581411 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1882797 |